The American Journal of Managed Care

Oral Peptides: FAQs on Bioavailability, Safety, and Clinical Use

As oral peptide therapies gain attention across metabolic health, sports performance, and longevity medicine, questions ...
Business Wire

Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies ...
Business Wire

Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that the Institutional Review Board (“IRB”) at ...
Nasdaq

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

Notes: Safety population, includes all randomized subjects who received at least one dose of study drug or placebo. Based on the encouraging weight loss, as well as the safety and tolerability results ...

Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma

Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma Recommendation based on positive results demonstrating ...
GEN

LNP Formulation System Scales from Clinical to Commercial Manufacturing

The success of the mRNA vaccines for COVID-19 led to explosive growth in lipid nanoparticle (LNP)-mediated drug delivery for RNA vaccines and therapeutics. As these projects scale into clinical trials ...
Nasdaq

Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone® Lispro Formulation Containing Insulin from Partner Tonghua Dongbao

LYON, France--(BUSINESS WIRE)-- Regulatory News: Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC, the “Company”), the biopharmaceutical company focused on the treatment of diabetes and other ...